A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
As a direct sampling technique, thermospray is able to gently ionize various types of analytes such that the resulting spectrum shows few fragments of the molecular ion and accompanying buffer gas components. This lack of fragmentation typically hinders the acquisition of structural information; however, thermospray is still capable of quantitative results and is valued for its range of viable analytes. When thermospray is coupled with high performance liquid chromatography mass spectrometry (TSP-HPLC-MS) the result is a highly sensitive method that is capable of lower detection limits than other HPLC-MS methods.
Neil Alan Dickson, MBE. Co-Founder, The Brain Tumour Charity. For services to People with Brain Tumours. Andrew James Dixon. Founding Trustee, Woodhaven Trust and Fairer Share and Founder, Arc InterCapital. For services to Prisoners and Ex-Offenders, to Property Tax Reform and to Entrepreneurship. Josephine Naomi Clare Dobrin. Co-Founder and Executive Chair, Creative Access. For services to the Creative Industries. Jonathan Donaghy. Deputy Director, Customs, HM Treasury. For Public Service. Amy Louise Doncaster. Deputy Director, Strategy and Future Design, Department for Work and Pensions. For Public Service. Terence Anthony Donnelly. Executive Chair, Donnelly Motor Group and Director, Taxi and Bus Conversions Ltd. For services to the Motor Industry in Northern Ireland. Professor Carol Ann Doyle. Lately Head of School for Nursing and Midwifery Education, Birmingham City University. For services to Nurse Education. Rachael Louise Doyle (Rachael Mills). Director, SE2 and Chirpy Heat. For services to Energy Efficiency and to Diversity and Inclusion. Philip Stephen Dudderidge. Co-Founder and Chair, Focusrite plc. For services to Business and to the Music Industry. Andrew Grant Duncan, DL. For services to the community in Worcestershire. Michael George Eakin. Chief Executive, Royal Liverpool Philharmonic. For services to Music and to the community in Liverpool, Merseyside. Catherine Louise Edwards. Lately Clinical Programmes Director, National Specialised Commissioning, NHS England. For services to the NHS. Emrys Shaun Elias.
==== Impact of phonation ==== The viscoelastic properties of human vocal fold lamina propria are essential for their vibration, and depend on the composition and structure of their extracellular matrix. Adult vocal cords have a layered structure which is based on the layers differential in extracellular matrix distribution. Newborns on the other hand, do not have this layered structure. Their vocal cords are uniform, and immature, making their viscoelastic properties most likely unsuitable for phonation. Hyaluronic acid plays a very important role in the vocal fold biomechanics. In fact, hyaluronic acid has been described as the extracellular matrix molecule that not only contributes to the maintenance of an optimal tissue viscosity that allows phonation, but also of an optimal tissue stiffness that allows frequency control. CD44 is a cell surface receptor for HA. Cells such as fibroblasts are responsible for synthesizing extracellular matrix molecules. Cell surface matrix receptors in return, feed back to the cells through cell-matrix interaction, allowing the cell to regulate its metabolism. Sato et al. carried out a histopathologic investigation of unphonated human vocal cords. Vocal fold mucosae, which were unphonated since birth, of three young adults (17, 24, and 28 years old) were looked at using light and electron microscopy. The results show that the vocal fold mucosae were hypoplastic, and rudimentary, and like newborns, did not have any vocal ligament, Reinke's space, or layered structure. Like newborns, the lamina propria appeared as a uniform structure.
=== Driver behavior === Highly developed fleet management and vehicle telematics systems collect a full range of data in real-time and for transport and fleet managers. By combining received data from the vehicle tracking system and the on-board computer, it is possible to form a profile for any given driver (average speed, frequency of detours, breaks, severity of manoeuvres, choice of gears, etc.). This data can be used to highlight drivers with dangerous habits and to suggest remedial training applicable to the issues, or to ensure that drivers are meeting KPIs. Fleet management apps have shown to reduce driving incidents.
Sources: en.wikipedia.org
== Purpose == The purpose of the GxP quality guidelines is to ensure a product is safe and meets its intended use. GxP guides quality manufacture in regulated industries including food, drugs, medical devices, and cosmetics. The most central aspects of GxP are good documentation practices (GDP), which are expected to be "ALCOA":
=== Mass Spectrometry === Mass spec techniques are essential in nuclear forensics analysis. Mass spec can provide elemental and isotopic information. Mass spec also requires less sample mass relative to counting techniques. For nuclear forensic purposes it is essential that the mass spectrometry offers excellent resolution in order to distinguish between similar analytes, e.g. 235U and 236U. Ideally, mass spec should offer excellent resolution/mass abundance, low backgrounds, and proper instrumental function.
=== Use of meloxicam in cats === The issue of using meloxicam in cats involves conflicting guidelines, differing legislation, and a narrow therapeutic safety margin that can easily turn the drug from cure to poison. More specifically:
=== September === 1 September – Education Secretary Jenny Gilruth confirms that Reinforced autoclaved aerated concrete (RAAC) has been found in 35 of Scotland's council-run schools after the roof of privately run Queen Victoria School in Dunblane had to be secured. The announcement follows revelations about the discovery of the concrete in schools in England, where more than 100 have been told to close affected buildings while repair work is carried out. 3 September – Neil Gray, Scotland's Wellbeing and Economy Secretary, says there is no immediate risk to schools in Scotland from defective concrete. 4 September – Connor Gibson is sentenced to life imprisonment with a minimum of 22 years for the sexual assault and murder of his sister, Amber Gibson, in November 2021. 5 September – First Minister Humza Yousaf outlines the programme for government legislation for the year ahead, including improvements to childcare, an extra £1bn for social security and pay improvements for social care staff. There are also plans to ban disposable vapes over environmental concerns. Former SNP MP Natalie McGarry is ordered to pay £66 for embezzling £25,000 from the SNP and a pro-independence group. 6 September – Nicola Sturgeon makes her first speech in the Scottish Parliament following her arrest in June. 7 September – Network Rail admits responsibility for a series of failings that led to the deaths of three people as a result of the Stonehaven derailment in August 2020. 8 September – Network Rail is fined £6.7m after admitting a series of failings that led to the Stonehaven train crash.
== Production of extracellular metabolites == Metabolites can be divided into two groups: those produced during the growth phase of the organism, called primary metabolites and those produced during the stationary phase, called secondary metabolites. Some examples of primary metabolites are ethanol, citric acid, glutamic acid, lysine, vitamins and polysaccharides. Some examples of secondary metabolites are penicillin, cyclosporin A, gibberellin, and lovastatin.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.